Blair William & Co. IL Decreases Position in DexCom, Inc. $DXCM

Blair William & Co. IL decreased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 4.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,109,343 shares of the medical device company’s stock after selling 98,701 shares during the quarter. Blair William & Co. IL’s holdings in DexCom were worth $141,938,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. First Trust Advisors LP raised its stake in DexCom by 19.3% in the third quarter. First Trust Advisors LP now owns 1,014,459 shares of the medical device company’s stock valued at $68,263,000 after buying an additional 163,818 shares during the last quarter. Neuberger Berman Group LLC grew its stake in shares of DexCom by 41.6% during the third quarter. Neuberger Berman Group LLC now owns 1,105,730 shares of the medical device company’s stock worth $74,405,000 after acquiring an additional 324,849 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of DexCom by 52.5% during the third quarter. Dimensional Fund Advisors LP now owns 1,444,566 shares of the medical device company’s stock valued at $97,187,000 after acquiring an additional 497,039 shares in the last quarter. Cresset Asset Management LLC increased its holdings in shares of DexCom by 19.1% during the third quarter. Cresset Asset Management LLC now owns 17,137 shares of the medical device company’s stock valued at $1,153,000 after acquiring an additional 2,754 shares in the last quarter. Finally, Picton Mahoney Asset Management raised its position in shares of DexCom by 12.8% in the 3rd quarter. Picton Mahoney Asset Management now owns 230,166 shares of the medical device company’s stock valued at $15,488,000 after purchasing an additional 26,106 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Weiss Ratings raised shares of DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday. Leerink Partners reaffirmed an “outperform” rating and issued a $92.00 price target on shares of DexCom in a report on Tuesday, December 16th. Robert W. Baird set a $87.00 price objective on shares of DexCom in a research note on Friday, February 13th. Canaccord Genuity Group set a $95.00 price objective on shares of DexCom and gave the company a “buy” rating in a report on Friday, February 13th. Finally, Sanford C. Bernstein reissued an “outperform” rating and issued a $86.00 target price (up from $84.00) on shares of DexCom in a research report on Friday, January 9th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $85.18.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $68.10 on Friday. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98. The business’s 50 day moving average price is $70.69 and its 200 day moving average price is $68.93. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45. The firm has a market cap of $26.21 billion, a P/E ratio of 32.43, a P/E/G ratio of 1.37 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The company had revenue of $1.26 billion during the quarter, compared to analyst estimates of $1.25 billion. During the same period last year, the firm posted $0.45 EPS. DexCom’s revenue for the quarter was up 13.1% compared to the same quarter last year. On average, sell-side analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.